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Abstract
Background: Tuberculosis (TB) remains a global health threat with 9 million new cases and 1.4 million deaths per
year. In order to develop a protective vaccine, we need to define the antigens expressed by Mycobacterium
tuberculosis (Mtb), which are relevant to protective immunity in high-endemic areas.
Methods: We analysed responses to 23 Mtb antigens in a total of 1247 subjects with different HIV and TB status
across 5 geographically diverse sites in Africa (South Africa, The Gambia, Ethiopia, Malawi and Uganda). We used a
7-day whole blood assay followed by IFN-γ ELISA on the supernatants. Antigens included PPD, ESAT-6 and Ag85B
(dominant antigens) together with novel resuscitation-promoting factors (rpf), reactivation proteins, latency (Mtb DosR
regulon-encoded) antigens, starvation-induced antigens and secreted antigens.
Results: There was variation between sites in responses to the antigens, presumably due to underlying genetic and
environmental differences. When results from all sites were combined, HIV- subjects with active TB showed
significantly lower responses compared to both TST- and TST+ contacts to latency antigens (Rv0569, Rv1733,
Rv1735, Rv1737) and the rpf Rv0867; whilst responses to ESAT-6/CFP-10 fusion protein (EC), PPD, Rv2029,
TB10.3, and TB10.4 were significantly higher in TST+ contacts (LTBI) compared to TB and TST- contacts fewer
differences were seen in subjects with HIV co-infection, with responses to the mitogen PHA significantly lower in
subjects with active TB compared to those with LTBI and no difference with any antigen.
Conclusions: Our multi-site study design for testing novel Mtb antigens revealed promising antigens for future
vaccine development. The IFN-γ ELISA is a cheap and useful tool for screening potential antigenicity in subjects with
different ethnic backgrounds and across a spectrum of TB and HIV infection states. Analysis of cytokines other than
IFN-γ is currently on-going to determine correlates of protection, which may be useful for vaccine efficacy trials.
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Introduction
Mycobacterium tuberculosis (Mtb) complex is the causative
agent of tuberculosis (TB). The scientific challenges in
understanding immunity to Mtb arise from the observation that,
although immune responses are generated after infection,
eradication of the bacteria is rare [1]. Instead, host immunity
causes Mtb to adopt a clinically silent, latent state of infection in
which it is highly resistant to immune attack. Once immunity
becomes dysregulated the bacteria can become reactivated
[1]. Considering that over 2 billion people live with latent TB
infection (LTBI) [2], this population provides an enormous
reservoir for potentially new cases of active TB disease.
The Mtb life-cycle can be separated into three main stages:
latent (dormant), reactivating and active TB. Each stage
represents differences in Mtb gene expression and therefore
determining the immune response to stage-specific antigens
can inform the design of new vaccine candidates [3,4]. For
instance, in LTBI, the Mtb DosR regulon is induced by
conditions that inhibit aerobic respiration and prevent bacillary
replication and is crucial for rapid resumption of growth by
involving resuscitation-promoting factors (rpf) once Mtb exits
the hypoxic/anaerobic or nitric oxide-induced non-respiring
state [5]. Once reactivation has occurred, the induction of a
strong immune response by the host may actually provide
further benefit to the bacteria [1–3]: T cell responses to TB
antigens have been shown to be significantly higher in active
TB than LTBI [6,7] suggesting that increased immunity may
promote lung pathology and subsequently transmission [1].
Indeed, immunogenicity does not necessarily equate to
protection, as illustrated by the recent failure of a novel prime-
boost vaccine, MVA85A, to protect children against TB [8],
despite a proven antigen-specific T cell response [9]. Thus,
more information is required to understand what constitutes
protective immunity to TB and in turn to inform new vaccine
design strategies.
Our consortium previously reported responses to 51 DosR
antigens in latently infected HIV-subjects from Uganda, South
Africa and The Gambia with Rv1733c being the most
commonly recognised antigen [10]. However, whilst similarities
between sites were observed, there were also significant
differences between the populations. Another study of South
African subjects showed that responses to rpf were significantly
higher in TB cases compared to household contacts (HHC) but
values were minute compared to responses to dominant
antigens such as ESAT-6/CFP-10 fusion protein (EC) [11] and
comprised a mixture of uninfected and latently infected HHC.
Building on these preliminary findings, the present study
analysed T cell responses to 23 Mtb antigens in a total of 1247
subjects with different HIV and TB status across five
geographically diverse sites in Africa (South Africa, The
Gambia, Ethiopia, Malawi and Uganda).
Methods
Ethics statement
This study was conducted according to the principles
expressed in the Declaration of Helsinki. Study protocols were
approved by specific review boards at each institution (full
details for each site are listed in the Table S1). All patients
provided written informed consent for the collection of samples
and subsequent analysis.
Subjects and Study sites
The study design for GC6-74 has been previously described
[12]. For this sub-study, sites included The Gambia (Medical
Research Council, MRC), Ethiopia (Armauer Hansen Research
Institute, AHRI), Malawi (Karonga Prevention Study, KPS),
Uganda (Makerere University, MAK) and South Africa
(Stellenbosch University, SUN). Subjects were considered for
inclusion if they were ≥18 years of age, had no concurrent
infections and were willing to undergo an HIV test. Subjects
without TB were recruited from households of TB patients
(MRC, SUN, and MAK) or by random community selection and
from HIV care clinics (KPS, AHRI) (termed household and
community controls; HCC). All subjects underwent a clinical
assessment, including a chest x-ray and a screen for malaria
and inter-current illnesses. Tuberculin skin tests (TST; two
tuberculin units [TU], PPD RT23, SSI, Denmark) were
performed in order to detect latent infection status in the
subjects without active disease. Subjects with induration
≥10mm for HIV- or ≥5mm for HIV+ subjects were classified as
latently infected (TST+). TB cases were confirmed by sputum
culture (BACTEC™, Becton-Dickinson, USA). If BACTEC was
not available, culture on Lowenstein-Jensen solid media was
performed (KPS, AHRI). Following informed consent,
heparinised whole blood was collected for the whole blood
assay set-up.
Seven-day whole blood assay
200µl of 1:10 diluted whole blood was stimulated with each
antigen in triplicate as previously described [10]. Each site
used the same batch of quality controlled antigens, controls
and reagents. The antigens used were generated by our
consortium and immunogenicity determined previously [10,13]
(Table S2). Following 7 days incubation at 37oC, 5% CO2,
supernatants were harvested and stored at -20oC prior to
analysis by IFN-γ ELISA. Antigens were evaluated at a final
concentration of 10µg/ml except for the peptide pools, Rv2659c
and Rv2660, which were used at 1µg/mL final concentration
per peptide and Mtb PPD, which was used at 5µg/mL final
concentration. Controls included unstimulated (negative
control) and the polyclonal stimulator, phytohaemagglutinin
(PHA 5µg/mL; positive control) (Sigma, USA). Antigens were
produced at SSI (Denmark) or LUMC (The Netherlands).
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IFN-γ ELISA
Supernatants were analysed by IFN-γ ELISA as previously
described [10,14]. Briefly, plates were coated overnight with
mouse anti-human IFN-γ monoclonal antibody (2µg/ml; Becton-
Dickinson, USA) at 4oC. Following washing with PBS-Tween
20, wells were blocked using PBS/FCS (Sigma, USA) for 2
hours. Samples, controls and standards were then added and
the plate incubated overnight at 37oC. After washing,
biotinylated anti-rabbit detection antibody (1µg/mL; Becton-
Dickinson, USA) was added, plates incubated for 45min. at RT
and a final colorimetric step performed by addition of avidin-
peroxidase followed by OPD Fast (Both from Sigma, USA).
The reaction was stopped with 2M H2SO4 and the plates were
read at 492nm with a four-parameter curve-fit. Each site used
an aliquot of the same positive PHA-stimulated whole blood
culture as a positive control. Additionally, the same batches of
antibodies and standards were used in all the sites, using a
standardised protocol.
Data analysis
We assumed non-parametric distribution of samples. All
antigen-stimulated wells were adjusted for non-specific
responses by background subtraction (media alone). IFN-γ
levels below 16pg/mL were considered as non-responses and
adjusted to ‘1’. A Kruskal-Wallis test followed by Dunn’s post-
test comparison was used for determining differences between
TB cases and TST+ and TST- HHC. A Mann–Whitney U-test
was used for analysis of TB cases and TST+ controls at each
site. Significance was defined as p-value ≤0.035 to adjust for
false-discovery rates (FDR) with multiple comparison testing.
For HIV+ subjects, analysis of CD4 counts within and between
sites was performed using Kruskal-Wallis test and Dunn’s post-
test comparison. Due to differences between sites in regards to
CD4 counts, HIV+ subjects were analysed both with
unadjusted and adjusted CD4 counts using linear regression.
Logistic regression and receiver-operator curve (ROC)
analyses were performed to determine which parameters best
discriminate between TB and TST+ controls. Analyses were
performed using Graphpad Prism 6 (Software MacKiev, USA)
and SPSSv20 (IBM, USA).
Results
Subject demographics
The majority of subjects in this study were HIV- with a total of
262 HIV-TB+, 454 HIV-TST+ (HCC) and 204 HIV-TST- HCC from
all sites combined (Table 1 depicts numbers from individual
sites). No HIV+ subjects were analysed from MRC due to the
low rate of HIV infection in The Gambia. For HIV-infected
subjects, a total of 77 TB, 87 TST+ HCC and 163 TST- HCC
were analysed (Table 1). There were significant differences
between and within sites in regards to age and sex of the
subjects so these were adjusted for accordingly in the
statistical analyses where possible. A total of 71 TB index
cases from MRC were also confirmed to be infected with either
Mtb sensu stricto (n=39) or M. africanum (Maf; n=32); a strain
only present in West Africa [15]. No significant difference in
response to any of the antigens was seen in Mtb or Maf
infected subjects (data not shown) and therefore this was not
adjusted for in our analyses. HIV+ subjects had significant
differences in CD4 counts within and between sites (Table 1).
Whilst no difference was seen for TB cases or TST+ HCC,
TST- HCC were significantly different between sites particularly
for SUN (p<0.05 compared to KPS and p<0.001 compared to
both AHRI and MAK). In addition, TB cases had significantly
lower CD4 counts compared to TST+ contacts at AHRI, KPS
and MAK (p=0.01, p=0.001 and p=0.0001 respectively) but not
at SUN. As such, results are presented using unadjusted
values, but also with adjustment for differences in CD4 counts.
Table 1. Participant information.
 HIV+ HIV-  
Site/TB
status TB TST+ TST- TB TST+ TST- Total
SUN 23 15 47 65 175 27 352
Age 34[28–40]
39[30–
44]
39[31–
47]
28[22–
40]
26[21–
33]
24[19–
37]  
% males 57 56 43 40 40 37  
CD4
cells/μL 191 184 153     
MRC n/a n/a n/a 77 120 124 321
Age n/a n/a n/a 28[23–39]
25[20–
34]
24[18–
31]  
% males n/a n/a n/a 85 50 56  
AHRI 19 18 15 31 28 11 122
Age 35[27–45]
30[25–
35]
32[24–
36]
23[21–
28]
31[20–
45]
23[20–
30]  
% males 41 14 20 65 36 27  
CD4
cells/μL 165 380 354     
KPS 21 39 78 32 34 18 222
Age 32[27–38]
39[31–
48]
39[31–
45]
49[29–
58]
39[32–
50]
34[27–
52]  
% males 52 33 36 56 51 44  
CD4
cells/μL 46 328 209     
MAK 14 15 23 57 97 24 230
Age 28[25–39]
35[31–
40]
30[27–
39]
25[22–
30]
26[19–
35]
22[20–
26]  
% males 43 13 30 49 43 38  
CD4
cells/μL 135 487 403     
Total
(n=) 77 87 163 262 454 204 1247
HIV+ = human immunodeficiency virus-positive; HIV– = human immunodeficiency
virus-negative; TB = active tuberculosis; TST+ = tuberculin skin test-positive
control; TST– = tuberculin skin test-negative control; SUN = Stellenbosch
University, South Africa; MRC = Medical Research Council, The Gambia; AHRI =
Armauer Hansen Research Institute, Ethiopia; KPS = Karonga Prevention Study,
Malawi; MAK = Makerere University, Uganda; Age = median[Interquartile range].
Total = total subjects per site per TB/HIV group. CD4 counts indicated for HIV-
positive subjects only.
doi: 10.1371/journal.pone.0074080.t001
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IFN-γ responses to 23 antigens following a 7-day whole
blood assay
Figure 1 shows a heat-map of responses from all sites with
subjects separated based on TB and HIV status. The highest
responses were to PHA, PPD, EC, TB10.4 and Rv2029c
(Figure 1, red). The heat map illustrates the differences seen
between sites, with subjects from AHRI showing responses
(median) to the majority of antigens used regardless of HIV or
TB status (Figure 1; AHRI); whilst KPS subjects responded to,
at most, four antigens other than PPD and PHA (HIV-LTBI:
Rv1733, Rv1735, Rv1737 and Rv2029) and only ESAT-6/
CFP10 (EC) for the other 3 groups (Figure 1; KPS). The most
consistent differences were seen to EC regardless of site, TB
or HIV status. However the direction differed between sites with
higher EC responses in TB patients compared to LTBI for both
HIV- and HIV+ subjects from AHRI and HIV- subjects from KPS
but lower responses to LTBI from all other sites regardless of
HIV status. After PHA, PPD and EC, the antigens that induced
the greatest number of responses from each group were
Rv2029c (20 out of a possible 24 HIV/TB groups) followed by
Rv1737c (17/24) and TB10.4 (16/24) (Figure 1).
Control Stimulants
Control antigens used in this study included PPD and the
mitogen PHA as a polyclonal stimulator. PPD cross-reacts with
both environmental Mycobacteria and BCG vaccine and
therefore is not specific for TB in the endemic countries
analysed in this study. Indeed, few differences were seen in
responses to PPD between TST+ controls (LTBI) and active TB
subjects (Figure 2). SUN was the only site to see a difference
between the groups in response to PPD: both HIV- (p<0.01)
and HIV+ (p<0.01) subjects with responses in active TB
disease being significantly lower than in LTBI. Responses to
the positive control PHA were significantly lower in subjects
with active TB disease compared to LTBI for all sites studied
regardless of HIV status. Intriguingly, these responses were
Figure 1.  Heat map of IFN-γ responses to secreted, latent, and reactivation Mtb antigens stratified according to HIV status,
TB status and location. .  Median levels of IFN-γ are shown (pg/mL). Red indicates relatively high levels of IFN-γ and blue
indicates relatively low levels. HIV+ = human immunodeficiency virus positive; HIV- = human immunodeficiency virus negative; TB =
active tuberculosis; LTBI = latently TB infected; n/d = not done; SUN = Stellenbosch University, South Africa; MRC = Medical
Research Council, The Gambia; AHRI = Armauer Hansen Research Institute, Ethiopia; KPS = Karonga Prevention Study, Malawi;
MAK = Makerere University, Uganda. The right column indicates the number of groups (out of a possible 24) who responded to a
particular antigen. PPD was not used at MAK nor was Ag85b used at SUN, so the maximum number for these is 20.
doi: 10.1371/journal.pone.0074080.g001
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often lower than for PPD (Figure 2). Whilst there was
considerable variation in PHA responses within and between
sites, we did not adjust for this since responses to PPD, which
reflect TB relevant immune responses, were not significantly
different.
Secreted antigens
The secreted Mtb antigens used in this study were EC,
Rv0288 (TB10.4), Rv1886 (Ag85b) and Rv3019 (TB10.3)
(Table S2). There were no significant differences between TB
and LTBI in response to these antigens with subjects from
AHRI (HIV- and HIV+; Figure 3). HIV- TB cases from KPS had a
significantly higher response to EC than LTBI (p=0.0035;
Figure 4A), but no difference in HIV+ subjects after adjusting
for FDR (Figure 4B). LTBI subjects from Uganda (MAK) had
significantly higher IFN-γ levels compared to TB following
TB10.3 and TB10.4 stimulation (p<0.0001 for both) in HIV-
subjects (Figure 5A) and following EC (p=0.0342) and TB10.3
(0=0.0013) stimulation in HIV+ subjects (Figure 5B). However,
when CD4 counts were adjusted, only TB10.3 responses were
significantly different (p=0.026). Ag85b responses were not
assessed in subjects from SUN, however, responses to EC
and TB10.4 were both significantly higher in HIV- LTBI
compared to HIV- TB (p=0.0109 and p=0.0001 respectively;
Figure 6A). Similarly, HIV+ LTBI subjects from SUN had higher
levels of IFN-γ in response to EC and TB10.4 than HIV+ TB
after adjusting for CD4 counts (p=0.003 and p<0.0001
respectively; Figure 6B). Due to low levels of HIV infection in
The Gambia, data from MRC is presented for HIV- subjects
only (Figure 7). Similar to AHRI and MAK, LTBI subjects from
MRC had higher responses to secreted antigens than those
with active TB with a significant difference in IFN-γ production
following stimulation with TB10.3 (p=0.0223) and TB10.4
(p=0.0001) and a higher (but not significant) response to EC
(Figure 7).
Reactivation antigens
The reactivation antigens used in this study were Rv1131,
Rv1471, Rv3407, Rv0867c, Rv1009 and Rv2450c (Table S2);
the latter three are so-called rpf proteins. Principally, responses
to these antigens were lower than for the secreted antigens
except for HIV- subjects from AHRI but, despite higher levels in
LTBI, there were no significant differences seen between the
groups for any antigen in HIV- or HIV+ subjects from AHRI
(Figure 3). HIV- LTBI from KPS showed significantly higher
responses than HIV-TB to Rv1131 and Rv0867c (p=0.0073
and p=0.006 respectively; Figure 4A). HIV+ subjects from KPS
showed low responses to all of the reactivation antigens except
Rv1009, which was significantly higher in LTBI than TB
(p=0.0060; Figure 4B). After adjusting for CD4 levels, Rv1131
was also significantly higher in LTBI compared to TB (p<0.035).
HIV- LTBI subjects from MAK revealed significantly higher
Figure 2.  IFN-γ secretion in response to secreted, latent, and reactivation Mtb antigens in active TB and LTBI subjects,
from five African sites.  IFN-γ ELISA was performed on supernatants collected after 7-day antigen stimulation of diluted blood
from TB cases (grey) and TST+ (LTBI) controls (white) from five sites in Africa. Line indicates median, whiskers indicate 5–95%
range and dots indicate outliers. Data were analysed by Mann-Whitney U-test within sites for HIV– and/or HIV+ subjects. Significant
differences are indicated: *=p<0.05; **=p<0.01; ***=P<0.001.
doi: 10.1371/journal.pone.0074080.g002
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responses to all reactivation antigens compared to HIV- TB
except Rv1471 and Rv2450 (Figure 5A). HIV+ LTBI subjects
from MAK had significantly higher levels of IFN-γ following
stimulation with Rv1131 and Rv1009 compared to TB
(p<0.0062 and p<0.0033 respectively; Figure 5B) but only for
Rv1009 after adjusting for CD4 counts (p=0.013). HIV- subjects
from SUN generated low responses to the reactivation antigens
(Figure 6A), although these were significantly higher in HIV- TB
compared to LTBI in response to Rv0867c (p=0.0020; Figure
6A). HIV+ subjects from SUN did not respond to any
reactivation antigen (Figure 6B) even after adjusting for CD4
counts. While all other sites had higher levels of response to
Figure 3.  IFN-γ secretion in response to secreted, latent, and reactivation Mtb antigens in active TB and LTBI subjects,
from Ethiopia.  IFN-γ ELISA was performed on supernatants collected after 7 day antigen stimulation of diluted blood from TB
cases (black) and TST+ (LTBI) controls (white) from AHRI (Ethiopia). Line indicates median, whiskers indicate 5–95% range and
dots indicate outliers. Data were analysed by Mann-Whitney U-test for HIV– and/or HIV+ subjects. Significant differences are
indicated.
doi: 10.1371/journal.pone.0074080.g003
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Rv0867c from LTBI compared to active TB, this was the
reverse for HIV- subjects from MRC (p=0.012; Figure 7).
Responses to Rv2450c followed the same pattern as for the
other sites with levels of IFN-γ significantly higher in LTBI than
TB subjects from MRC (p=0.0042; Figure 7).
Latency antigens
Latency (i.e. Mtb DosR regulon-encoded) antigens included
in this study were Rv0081, Rv0569, Rv1733c, Rv1735c,
Rv1737c, Rv2028c, Rv2029c, Rv2031c, and Rv3131c, next to
the two starvation-induced antigens Rv2659c, Rv2660c. Whilst
HIV- subjects from AHRI showed no significant difference
between LTBI and TB to any of these antigens (although LTBI
were generally higher than TB), HIV+ LTBI had a significantly
Figure 4.  IFN-γ secretion in response to secreted, latent, and reactivation Mtb antigens in active TB and LTBI subjects,
from Malawi.  IFN-γ ELISA was performed on supernatants collected after 7-day antigen stimulation of diluted blood from TB cases
(black) and TST+ (LTBI) controls (white) from KPS (Malawi). Line indicates median, whiskers indicate 5–95% range and dots
indicate outliers. Data were analysed by Mann-Whitney U-test for HIV– and/or HIV+ subjects. Significant differences are indicated.
doi: 10.1371/journal.pone.0074080.g004
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higher response to Rv1735c than HIV+ TB (p=0.0012; Figure
3B); although this was lost after adjusting for CD4 counts. HIV-
LTBI from KPS generated significantly higher responses to
Rv0569, Rv1733c, Rv1735c and Rv1737c than HIV- TB
(p=0.0023, p=0.0023, p=0.0014 and p<0.0001 respectively;
Figure 4A). Additionally, HIV+ LTBI from KPS revealed
significantly higher responses to Rv1733 and Rv2029c and
Rv2031c than HIV+ TB (p=0.0059, p=.0318 and p=0.0265
respectively; Figure 4B); but again no difference after adjusting
for CD4 counts. HIV- LTBI from MAK had significantly higher
levels of IFN-γ than HIV- TB following stimulation with all the
latency antigens used in this study (Figure 5A). HIV+ LTBI also
had higher responses than HIV+ TB to most of the latency
antigens with significant differences found for Rv1733c,
Rv1735c, Rv1737c and Rv2029c (p=0.0023, p=0.0018,
p=0.0031 and p=0.0008 respectively; Figure 5B). After
adjusting for CD4 counts, Rv1737c and Rv2029c remained
significantly different between LTBI and TB (p=0.011 and
p=0.003 respectively). HIV- LTBI subjects from SUN had
Figure 5.  IFN-γ secretion in response to secreted, latent, and reactivation Mtb antigens in active TB and LTBI subjects,
from Uganda.  IFN-γ ELISA was performed on supernatants collected after 7-day antigen stimulation of diluted blood from TB
cases (black) and TST+ (LTBI) controls (white) from MAK (Uganda). Line indicates median, whiskers indicate 5–95% range and dots
indicate outliers. Data were analysed by Mann-Whitney U-test for HIV– and/or HIV+ subjects. Significant differences are indicated.
doi: 10.1371/journal.pone.0074080.g005
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significantly higher levels of IFN-γ compared to HIV- TB
subjects in response to Rv0569, Rv1733c, Rv1737c and
Rv2029c (Figure 6A). Again, HIV+ subjects from SUN showed
no differences in response to any of the latency antigens
between LTBI and TB (Figure 6B). Whilst MRC subjects
generated lower responses to most of the latency antigens
than HIV- subjects from AHRI, MAK and SUN, they were
significantly higher in LTBI compared to active TB subjects in
response to Rv0569, Rv1733c, Rv1735c and Rv1737c.
Comparison of TST- (Mtb-uninfected), TST+ (LTBI) and
active TB groups
We analysed HIV- and HIV+ subjects from all sites based on
their TB status (Mtb-uninfected (TST-), latent infection (TST+) or
active disease (TB)). For HIV- subjects, active TB subjects had
significantly lower levels of IFN-γ compared to both TST- and
TST+ controls in response to latency antigens Rv0569, Rv1733,
Rv1735, Rv1737 and Rv0867 (p<0.0001 for all; Figure 8).
Responses to EC and PPD were significantly higher in HIV-
TST+ (LTBI) compared to HIV- TB subjects (p=0.016 and
Figure 6.  IFN-γ secretion in response to secreted, latent, and reactivation Mtb antigens in active TB and LTBI subjects,
from South Africa.  IFN-γ ELISA was performed on supernatants collected after 7-day antigen stimulation of diluted blood from TB
cases (black) and TST+ (LTBI) controls (white) from SUN (South Africa). Line indicates median, whiskers indicate 5–95% range and
dots indicate outliers. Data were analysed by Mann-Whitney U-test for HIV– and/or HIV+ subjects. Significant differences are
indicated. n/d = antigen not analysed.
doi: 10.1371/journal.pone.0074080.g006
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p<0.0001 respectively) who were in turn, significantly higher
than HIV- TST- subjects (p<0.0001 for both; Figure 8).
Responses to Rv2029, TB10.3, TB10.4 and PHA were
significantly higher in HIV- TST+ compared to both HIV- TB and
HIV- TST- (who were comparable; p<0.0001 for all; Figure 8).
Fewer differences were seen with HIV+ subjects: the only
significant difference between TB and TST+ subjects was in
response to PHA with a median of 193 pg/mL for HIV+ TB+
compared to 2799 pg/mL for HIV+ TST+ (p<0.0001; Figure 8).
Similar to the HIV- subjects, we observed a hierarchical
response to EC and PPD with LTBI higher than TB (but not
significantly) and both significantly higher than HIV+ TST-
(p<0.0001 for all; Figure 8). When ROC analysis was
performed, no single antigen response could discriminate
between active TB disease and latent infection with >65%
correct classification regardless of HIV status (data not shown).
Discussion
Discovery of new antigens that could provide protection
against primary or reactivation TB disease is essential for
development of next-generation vaccines. The fact that BCG
remains the only licensed TB vaccine for over 90 years shows
how difficult this accomplishment is. A recent trial using Mtb
Antigen 85A as a boost to BCG in infants showed no increase
in protection against development of TB, despite strong
immunogenicity in Phase I/IIa trials [8]. Thus we also need to
determine the exact correlates of protection to determine which
antigens to incorporate in vaccine design strategies and for
determining vaccine efficacy without the requirement for
extremely large and expensive cohort studies. The Bill &
Melinda Gates Foundation, Grand Challenges (GC) in Global
Health, Biomarkers for TB: GC6-74 aims to determine
biomarkers for protective immunity in the context of HIV/AIDS
in Africa (http://www.biomarkers-for-tb.net/consortium). As one
objective, we analysed responses from 1247 subjects to 23
Mtb antigens to elucidate the influence of TB status (latent
infection, Mtb-uninfected, active TB disease), HIV status and
geographical location on these responses.
The antigens analysed included PPD, ESAT-6 and Ag85B
together with novel rpf, reactivation proteins, latency (Mtb
DosR regulon-encoded) antigens, starvation-induced antigens
and secreted antigens tentatively characterized for T-cell
responses in HIV- HHC in a previous pilot study of 86 antigens
[10]. Antigens used in current diagnostic/vaccination strategies
(TB10.4, PPD and ESAT-6/CFP-10) generated dominant
responses from all sites but very few differences between
active TB disease and LTBI. The next highest responses were
seen to Rv2029c followed by Rv1733, Rv1735 and Rv1737.
These are all dormancy-associated antigens, essential for the
survival of Mtb during persistence in vivo and Rv1733, 1735
and 1737 were previously shown to induce dominant
immunogenic responses in a small cohort of LTBI subjects
from The Gambia, South Africa and Uganda [10]. Rv2029c is
Figure 7.  IFN-γ secretion in response to secreted, latent, and reactivation Mtb antigens in active TB and LTBI subjects,
from The Gambia.  IFN-γ ELISA was performed on supernatants collected after 7-day antigen stimulation of diluted blood from TB
cases (black) and TST+ (LTBI) controls (white) from MRC (The Gambia). Line indicates median, whiskers indicate 5–95% range and
dots indicate outliers. Data were analysed by Mann-Whitney U-test for HIV– subjects. Significant differences are indicated.
doi: 10.1371/journal.pone.0074080.g007
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Figure 8.  Heat map of combined responses from all sites for TST–, TST+ (LTBI) and active TB with or without HIV infection
in response to secreted, latent, and reactivation Mtb antigens. .  Median levels of IFN-γ are shown (pg/mL). Red indicates
relatively high levels of IFN-γ and blue indicates relatively low levels. HIV+ = human immunodeficiency virus positive; HIV- = human
immunodeficiency virus-negative; TB = active tuberculosis; LTBI = latently TB infected; SUN = Stellenbosch University, South
Africa; MRC = Medical Research Council, The Gambia; AHRI = Armauer Hansen Research Institute, Ethiopia; KPS = Karonga
Prevention Study, Malawi; MAK = Makerere University, Uganda.
doi: 10.1371/journal.pone.0074080.g008
Understanding Protective Immunity to TB
PLOS ONE | www.plosone.org 11 September 2013 | Volume 8 | Issue 9 | e74080
probable phosphofructokinase (pfkB) and is one of the most
important enzymes of glycolysis [16]. A recent study suggests
that glycolysis leads to accumulation of glucose-derived toxic
metabolites that limits long-term survival of Mtb under hypoxic
conditions [16] and is exacerbated when the glycolytic pathway
is disrupted at the PKF step. Whilst HIV+ and HIV- subjects
from Uganda and HIV+ subjects from Malawi showed significant
differences between LTBI and TB to Rv2029c, no differences
were observed at the other three sites. This pattern was similar
for the majority of antigens used in this study: whilst there were
similarities between sites, there were also many differences.
Notably, these included no differences between TB and LTBI in
subjects from Ethiopia for any antigen, and much lower
responses to all antigens in subjects from Malawi. Note that
these differences between sites are unlikely due to differences
in Mtb strain since Gambian subjects infected with Mtb sensu
stricto or M. africanum showed no differences in response to
any of the antigens (data not shown). There was a large
variation in CD4 counts for HIV+ subjects within and between
sites, which will clearly affect levels of IFN-γ. However, whilst
HIV+ subjects from KPS had the lowest responses (and CD4
counts), HIV negative subjects from KPS also had very low
responses across the board. Additionally, subjects from SUN
showed no difference in CD4 levels between HIV+LTBI and
HIV+TB but were the only site to show a difference in
responses to PPD with active cases significantly lower than
LTBI regardless of HIV status. Even after adjusting for CD4
counts, there was still considerable variation between sites in
regards to antigen reactivity suggesting that other confounding
factors need to be considered such as ethnicity (host genetics),
nutritional status and microbial environment.
Although accuracy of combined analyses from all sites were
impeded by considerable variations in responses, the main
purpose of this study was the search for antigens which
distinguish between TST-, TST+ (LTBI) subjects and TB
patients regardless of geographical location (and hence of
ethnicity, nutritional status, microbial environment, etc.). When
results from all sites were combined, HIV- patients with active
TB showed significantly lower responses compared to both
TST- and TST+ (LTBI) contacts to latency antigens (Rv0569,
Rv1733, Rv1735, Rv1737) and the rpf Rv0867; whilst
responses to EC, PPD, Rv2029, TB10.3, TB10.4 and PHA
were significantly higher in TST+ HCC (LTBI) compared to
active TB and TST- HCC. Fewer differences were seen in
subjects with HIV co-infection, with response to PHA being
significantly lower in subjects with active TB compared to those
with LTBI and no difference with respect to any other antigen.
Interestingly, PHA-induced polyclonal responses were often
lower than PPD-induced responses to Mtb. This may relate to
the highly activated immune system of TB cases making their T
cells more susceptible to activation-induced cell death [17] with
PHA-induced IFN-γ inversely correlating with disease severity
[18].
Interestingly, the heat-shock protein, Rv2031c, which was
recently used as a post-exposure sub-unit vaccine enteric to M.
avium infection in cattle [19], induced low responses in our
study with the only difference seen for HIV+ subjects from KPS
(LTBI higher than TB). However, protection induced by
Rv2031c in cattle was shown to be mediated by antibodies
rather than T cells [19], emphasizing the importance for multi-
parametric analysis of responses to novel vaccine candidates.
Since the inception of this study, dominant Mtb antigens
were reported to be evolutionary hyperconserved [1,20] leading
to the suggestion that immunogenicity to these antigens could
benefit survival of Mtb. Disparities in responses between sites
in our study despite a large cohort, and the relatively few
differences seen between TB and LTBI, regardless of HIV
status, suggests that new Mtb epitope discovery is required for
determining the optimal candidates for development of novel
vaccines [21,22]. Furthermore, underlying genetic influences
are clearly playing a role since responses differed considerably
between sites despite the use of the same batch of reagents
for all assays and adjusting for age, sex and other
confounders. The fact we saw few differences between TB and
LTBI in this study may be explained partly by the use of a long-
term culture assay, which will detect both effector and central
memory cells. This may mean we are analysing responses to
antigens which were expressed during the asymptomatic stage
but which could not prevent progression to active disease in
the TB cases. Additionally, we only measured IFN-γ in our
study, which is required but not sufficient to protect against TB
disease [23]. As such, we are currently assessing levels of
cytokines other than IFN-γ in each of the culture supernatants
to determine correlates of protection, which may be used for
future vaccine efficacy trials.
In conclusion, we have shown the utility of performing large,
multi-site studies for TB research. The IFN-γ ELISA is a cheap
and useful tool for screening potential antigenicity in subjects
across the spectrum of TB and HIV infection. These studies
allow critical evaluation of responses to TB antigens in a large
cohort of subjects with different TB and HIV status and genetic
backgrounds: essential for finally elucidating what constitutes
protective immunity to TB.
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